There is no single established response time for all stem cell treatments. The cell preparation, diagnosis, treatment route, rehabilitation and outcome being measured all affect how results are assessed.
Beike’s FAQ describes three to six months as an expected period for changes, with some patients reporting further changes over a year. Its condition pages give different estimates. These are provider expectations and should not be presented as validated deadlines for an individual patient.
What Beike’s follow-up data shows
Beike’s October 2026 cerebral palsy report covers 640 forms from 256 patients and 302 treatment courses. Follow-ups included assessments at one, three, six and twelve months.
| Follow-up point | Forms reporting improved physical condition | Forms reporting improved quality of life |
|---|---|---|
| 1 month | 83.0% | 81.8% |
| 3 months | 82.4% | 82.5% |
| 6 months | 81.4% | 89.1% |
| 12 months | 79.6% | 85.3% |
Each time point contains a different set of forms. These percentages describe submitted answers, rather than the proportion of all treated patients who improved. The records have no untreated comparison group and cannot separate the effects of cells, rehabilitation, development or other care. They cannot establish when improvement began or predict an individual response.
Beike cerebral palsy follow-up report
Assessment periods in published research
| Condition and treatment studied | Assessment period | What the findings support |
|---|---|---|
| Cerebral palsy; umbilical cord blood | 6 and 12 months | A 2025 analysis found higher average gross motor function scores in treated participants than controls |
| Autism; intravenous cord blood | 6 months | A blinded trial of 180 children found no overall improvement in its primary social communication outcome |
| Autism; intrathecal bone marrow mononuclear cells plus education | 12 months | A 2025 open-label randomized trial reported improvements relative to education alone; it examined a different preparation from Beike’s cord-derived cells |
The cerebral palsy analysis reported between-group differences of 1.36 GMFM-66 points at six months and 1.42 points at twelve months. These are average differences on a motor assessment scale. They do not specify an individual child’s expected gain or the timing of maximum benefit.
The autism studies used different cells, delivery routes and designs. Their findings do not establish a standard three-to-six-month response time for Beike’s protocols.
What individual reports can establish
Beike publishes case reports with assessments over several months. An ataxia report describes changes at one, six and twelve months; a spina bifida report includes changes at one and three months. These accounts describe individual experiences without a control group. They cannot establish a typical response time for everyone with either diagnosis.
The available material does not justify assigning universal full-effect deadlines of one to five years to the conditions listed in the previous version of this article.
How to assess progress
Agree on specific goals and measurements before treatment. Depending on the diagnosis, these may include a motor assessment, visual acuity, walking distance, assistance needed for daily activities or a validated communication measure.
Record the baseline and use comparable assessments during follow-up. Document changes in medication, rehabilitation and other treatments alongside the results. Some patients report improvement, some report no change and some report worsening. Deterioration should receive medical assessment promptly.
Treatment approvals are specific
Approval of one cell product does not establish effectiveness for another product or diagnosis. For example, the FDA approved the MSC product Ryoncil in December 2024 for steroid-refractory acute graft-versus-host disease in children aged two months and older. That indication does not establish response times for Beike’s neurological treatment protocols.
Before treatment, ask which published evidence matches the proposed cells, route and diagnosis, how progress will be measured, and when the plan will be reviewed if there is no measurable benefit.
